Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label continued QTI571 (imatinib) treatment in PAH extension participants
2013-001100-10Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Novartis. Primary endpoint: Continued access to imatinib for PAH patients. Started Nov 2013; status: terminated.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2013-001100-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001100-10.